Navigation Links
AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
Date:1/24/2008

CARLSBAD, Calif., Jan. 24 /PRNewswire/ -- AutoGenomics, a leader in developing automated molecular testing solutions announced today that it has obtained clearance from the Food and Drug Administration (FDA) for its INFINITI 2C9-VKORC1 Multiplex Assay for Warfarin. The company has already received FDA clearance for its INFINITI Analyzer and FII/FV assays in 2007.

"We are excited to receive FDA clearance for our warfarin test," said Fareed Kureshy, President and CEO of AutoGenomics. "The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower the risk of bleeding complications. Several of our customers are awaiting such clearance to implement testing in their practice. We continue to expand our product portfolio with additional warfarin assays and are committed to be the lead player in this testing arena."

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. http://www.autogenomics.com


'/>"/>
SOURCE AutoGenomics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
2. ImmunoVaccine Technologies Receives $3 Million From ACOA
3. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
4. Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
5. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
6. Novadaqs SPY System receives clearance for use in organ transplant surgery
7. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
8. e-Health Card Terminal From SCM Microsystems Receives GEMATIK Certification
9. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
10. LifeMasters Receives Full URAC Disease Management Accreditation
11. Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has issued an important reminder to employers to ... Employers with workers exposed to high temperatures should establish a complete heat ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: